Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncorine + Tislelizumab + Lenvatinib in Advanced HCC
NCT05675462Phase 1Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Oncorine in hepatocellular carcinoma (HCC), sponsored by Fudan University. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose and 3 more. Started Mar 2023; status: recruiting.
02
Drugs
Oncorine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05675462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675462.